In countries where avian influenza has become endemic, early vaccination of layer pullets or broilers with classical inactivated vaccines at the hatchery is no longer an option because of interference with passive immunity indirectly induced by the necessary vaccination of the breeders. On the other hand, injection of thousands of chicks from 7 to 10 days old on farms has been determined to be unreliable and, therefore, poorly efficacious. For these reasons, interest has arisen regarding a newly developed live recombinant vector vaccine based on a turkey herpesvirus (HVT) expressing the H5 gene from a clade 2.2 H5N1 highly pathogenic avian influenza virus (HPAIV) strain (rHVT-H5), which in theory is capable of breakthrough passive immunity to both the vector (HVT) and the insert (H5) and is consequently applicable at the hatchery. The objectives of this trial were to evaluate the impact of maternally derived antibodies (MDAs) specific to H5N1 on the immunity and the efficacy (protection and virus shedding) of different vaccination programs including rHVT-H5 and inactivated H5N1 and H5N2 vaccines applied alone or in combination. Therefore, broilers carrying MDAs against both HVT and Asian H5N1 HPAIV were vaccinated on the first day of age with rHVT-H5, with or without boosting vaccination by an inactivated vaccine after 10 days. The different groups were challenged with two antigenically highly divergent Egyptian dade 2.2.1 H5N1 HPAIVs at 4 wk of age. Protection against challenge was compared with unvaccinated birds or vaccinated birds without MDAs. Between 70% and 90% clinical protection could be observed in the vaccinated groups possessing MDAs, indicating no or very low interference of MDAs with vaccination. Results regarding clinical protection, humoral, cell-mediated, and mucosal immunity, as well as re-excretion of challenge virus are presented and discussed.
SummaryBirds play a central role in WNV epidemiology by spreading and amplifying the virus. Increasing numbers of WNV isolates are detected in Europe, and the virulence of these genetically variable isolates is not well characterized for birds. Therefore, we investigated whether SPF chickens could be a valuable avian model for the pathotyping of WNV strains. One-day-old SPF chickens were inoculated subcutaneously (SC) or intracerebrally (IC) with four lineage 1 WNV strains (Is98, It2008, Fr2000 or Kunjin) and were daily clinically monitored for 2 weeks after infection. Additionally, one-day-old SPF chickens were SC inoculated, and one-week-old SPF chickens were SC or IC inoculated with two Euro-Mediterranean isolates, Is98 and Fr2000, to sample blood and feathers at regular time points. These samples were analysed by WN NS2a-specific rRT-PCR and WN NS1 antigen-capture ELISA that were developed for the purpose of this study. Differences in strain virulence were evidenced after IC inoculation of oneday-old SPF chickens, with Is98 eliciting the highest mortality rates and Kunjin the lowest ones, while lethality of Fr2000 and It2008 was intermediate. Neither viral load in sera and feathers nor NS1 antigen in the serum correlated with the differential pathogenicity of Is98 and Fr2000. However, irrespective of the inoculated strain, younger chickens showed higher and longer-lasting viremias than older chickens. In all experimental groups, the detection window for viral RNA in feathers lasted up to 14 dpi. Altogether, the data presented in this study show that WNV strain virulence can be discriminated in a one-day-old SPF chicken model on the basis of mortality rates, while viremia and viral load in feathers appear to be age dependent rather than strain dependent.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.